Astrocytic SIRT1 ameliorates cognitive deficits after traumatic brain injury via autophagy-mediated MEGF10 phagocytosis Authors: Qianxin Ji, Yan Zhang, Zhuo Zhang, Kun Cui, Liang Zhao, Xiaoyu Sun, Huiling Qu, Jia Song, Jianru Xiao, Xiaobin Zhang, Yu Lu, Jianan Xu, Dan Li Published: 2025 ABSTRACT AbstractTraumatic brain injury (TBI) frequently causes cognitive dysfunction, with astrocytes playing a pivotal role in its pathogenesis. ​Specifically,​​ TBI triggers excessive astrocyte reactivity, ​leading to a phagocytic phenotype in astrocytes that contributes to abnormal synaptic phagocytosis and cognitive decline. ​Sirtuin 1 (SIRT1) reduction was region-specific, with significant downregulation observed in the hippocampus and cortex, reflecting the selective vulnerability of these regions to TBI-induced pathology. Although​ SIRT1 ​is​ a neuroprotective deacetylase, its regulatory mechanism in post-TBI astrocyte phagocytosis remains unclear. This study elucidates the mechanism through which SIRT1 attenuates TBI-induced cognitive deficits, specifically by ​​promoting autophagic flux in astrocytes​​ and subsequently ​​suppressing MEGF10-mediated synaptic phagocytosis​​. The investigation leveraged a combination of clinical human samples and astrocyte-specific murine models, including SIRT1-overexpression and ATG7-knockdown systems. Crucially, ​​astrocyte-specific knockdown of ATG7​​ was employed to mechanistically demonstrate that the SIRT1-driven degradation of MEGF10 and the consequent synaptic preservation are ​​strictly dependent on a functional autophagy pathway​​, as evidenced by the complete abolition of SIRT1’s beneficial effects upon ATG7 knockdown. ​Methodologies included​ Western blotting, immunofluorescence, behavioral tests (Barnes maze), and in vitro assays. Notably, TBI ​significantly​ reduced SIRT1 levels; astrocytic SIRT1 overexpression ​suppressed​ MEGF10 expression via ATG7-dependent autophagy, ​thereby​ alleviating astrogliosis, synaptic loss, and cognitive deficits. ​Critically, these protective effects were abrogated by​ ATG7 knockdown. ​Collectively, our results define​ the SIRT1-autophagy-MEGF10 axis ​as a key regulator​ of astrocytic phagocytosis, ​revealing​ a novel therapeutic target for injury-related cognitive dysfunction.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12974-025-03633-x.Keywords: Astrocytic phagocytosis, Traumatic brain injury, Cognitive deficits Introduction Traumatic brain injury (TBI), a multifaceted pathological condition resulting from the direct application of external mechanical forces to the head, stands as a significant global contributor to both morbidity and mortality [1]. Within the realm of TBIs, closed head injury (CHI), a prevalent subtype, exerts profound impacts, extending beyond primary brain tissue damage to trigger a cascade of enduring secondary pathological changes [2, 3]. These alterations propagate through neural circuits, culminating in neurological impairments, behavioral changes, and persistent cognitive deficits [4–6]. Therefore, a thorough exploration of the pathophysiological mechanisms underpinning TBI holds immense value for the advancement and refinement of neurotherapeutic interventions. TBI is the most significant non-genetic, non-aging-related risk factor for Alzheimer’s disease (AD). Situated as a central node within the intricate neural network, the hippocampus is pivotal to cognitive function, with its integrity crucial for the maintenance of typical cognitive processes [7, 8]. Regrettably, the hippocampus is particularly vulnerable to the ravages of TBI, as evidenced by clinical associations between diminished hippocampal volume, TBI severity, and subsequent neurofunctional impairments [9, 10]. Following a TBI, the hippocampus experiences heightened cellular apoptosis, inflammatory responses, and synaptic reorganization, presenting promising avenues for therapeutic intervention to alleviate TBI-induced cognitive deficits. Astrocytes, integral components of the central nervous system, mount rapid responses to brain insults, transitioning from a quiescent to a highly reactive state marked by substantial morphological and functional changes [11–14]. This activation involves cytoskeletal remodeling, cellular volume expansion, and extension of astrocytic processes, which enhances their capability to clear cellular debris and toxic substances from the injured site. Concurrently, the upregulation of phagocytosis-related molecules further facilitates this process, underscoring the indispensable role of astrocytes in brain injury recovery [15]. Nevertheless, excessive astrocyte reactivity can yield deleterious outcomes, particularly concerning synaptic equilibrium [16, 17]. Under normal conditions, astrocytes collaborate with microglia to meticulously refine synaptic connections through phagocytosis, eliminating redundant or dysfunctional synapses to optimize neural circuitry and function [18, 19]. In the context of TBI or neurodegenerative disorders like AD, this delicate phagocytic balance may be disrupted, leading to excessive synaptic pruning and subsequent cognitive and motor dysfunction [15–17, 20, 21]. Sirtuin 1 (SIRT1), a pivotal deacetylase, has received escalating attention for its capacity to modulate astrocyte function and confer neuroprotection following brain injury [22–24]. Through protein modification, SIRT1 delicately regulates signaling pathways associated with phagocytosis [25, 26], inflammation [27, 28], and cellular activation [24, 26], thereby curbing excessive astrocyte reactivity and showcasing antioxidant and anti-inflammatory protective properties. Previous studies have preliminarily shown that SIRT1 overexpression in the peri-injury cortex substantially enhances motor functional recovery post-TBI [23, 24, 29]; however, the precise mechanisms governing its modulation of cognitive impairments remain elusive. This current study delves into the expression dynamics of SIRT1 in astrocytes post-TBI and its associated neuroprotective effects. Our investigation reveals a close correlation between decreased SIRT1 expression, heightened astrocytic activation, and increased synaptic phagocytosis. By elevating SIRT1 expression, we successfully attenuated astrocytic hyperactivation, minimized excessive synaptic pruning, and consequently facilitated cognitive recuperation. Importantly, our findings unveil a novel mechanism wherein SIRT1 regulates the expression of multiple EGF-like-domains 10 (MEGF10), a pivotal molecule in astrocytic phagocytosis [17, 18, 30], by enhancing autophagy instead of ubiquitination, thereby exerting neuroprotective effects post-TBI. These discoveries not only deepen our comprehension of SIRT1’s role in neuroinflammation and synaptic equilibrium but also furnish a robust theoretical framework and empirical evidence for the formulation of SIRT1-centered therapeutic approaches against TBI and neurodegenerative ailments, including AD. Materials and methods Animals C57BL/6J (8–10 weeks, 22–25 g; Certification No. SCXK 2020-0015) and Aldh1l1CreERT2/+ mice transgenic mice (Stock No. C001288) were procured from Beijing Huafukang Biotech and Cyagen Biosciences (Suzhou), respectively. After one-week SPF acclimatization, mice were maintained in IVC cages (Tecniplast; 6/cage) under controlled conditions: 22 ± 1 °C, 55 ± 5% humidity, 12-h light-dark cycle (07:00–19:00 light phase).​. All experimental protocols (Approval No. CMU2023314) were carried out in line with the IACUC guidelines of China Medical University, following ARRIVE 2.0 reporting standards. Procedures were performed under isoflurane anesthesia (4% for induction, 1.5% for maintenance in 100% O2) with buprenorphine analgesia (0.05 mg/kg s.c. every 12 h). Euthanasia was achieved via cervical dislocation under deep anesthesia (5% isoflurane for 3 min), confirmed by absence of pedal reflex. The study strictly adhered to the accreditation standards of the Institutional Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC, Certification No. 001356) and Chinese national guidelines (GB/T 35823 − 2018) throughout. Sex as a biological variable In the study, male mice (C57BL/6J, 8–10 weeks old) were used for all animal experiments unless otherwise specified. The choice of a single sex was driven by the need to minimize variability introduced by sex hormones, particularly given the focus on acute inflammatory and synaptic mechanisms post-TBI, which may be influenced by estrogen/progesterone fluctuations [31–34]. Human tissue samples included both sexes (see Supplemental Methods for details), but sex-specific analyses were not performed due to limited sample size. While the current findings establish a mechanistic framework, future studies will explicitly address sex differences in SIRT1-mediated astrocyte function to determine generalizability across sexes [35, 36]. Stereotaxic viral delivery and FITC administration Mice were anesthetized with 3% isoflurane and fixed in a stereotaxic apparatus. Hippocampal CA1 injections (ML + 1.5 mm, AP − 2.0 mm, DV − 1.7 mm) delivered AAVs (0.1–0.2 µL/min) or FITC (100-nm polystyrene microspheres, excitation/emission: 495/520 nm) 5 µL at 0.2 µL/min ipsilateral to the injury site. Needles were slowly withdrawn to prevent reflux. Post-surgical care included analgesia and thermal support. Viral expression was confirmed by immunofluorescence 3–4 weeks post-injection. Details and lists of AAVs are presented in Supplemental Methods and Supplemental Tables. Inducible astrocyte-specific SIRT1 Overexpression with ATG7 knockdown Aldh1l1CreERT2/+ mice received hippocampal co-injections of Cre-dependent SIRT1 and ATG7-shRNA AAVs. Tamoxifen (75 mg/kg, 5 days i.p.) induced recombination. TBI was performed 14 days later, with astrocyte specificity validated by GFAP/SIRT1 co-staining. Details are presented in Supplemental Methods and Supplemental Tables. Experimental TBI model A closed-head TBI model was established using a Benchmark™ stereotaxic impactor (Precision Systems and Instrumentation) to deliver a controlled cortical impact via a free-falling weight, consistent with well-characterized preclinical models of focal brain injury [37, 38]. Briefly, mice underwent anesthesia and securely positioned in a stereotaxic frame equipped with ear bars and a nose clamp to ensure strict head stabilization. The impact was delivered using a 3-mm flat tip at a velocity of 4.0 m/s to a depth of 1.5 mm beneath the dura, with a dwell time of 400 ms, under intact skull conditions. The stereotactic coordinates targeted the right hemisphere relative to bregma: medial-lateral (ML) + 1.50 mm, anterior-posterior (AP) − 2.00 mm, and dorsal-ventral (DV) − 1.20 mm. This paradigm induces consistent focal contusion without underlying skull fracture or excessive hemorrhage. Complete procedural details and setup schematics are provided in the Supplemental Methods and Supplemental Fig. 1A-B. Behavioral assessments Open Field Test: Mice were habituated to a controlled environment (23 °C, 55% humidity) for 2 h before testing in a 50 × 50 cm arena under 50 lx illumination. Locomotor activity (total distance, velocity) and anxiety-like behavior (time in center zone) were recorded for 5 min using an infrared tracking system (VisuTrack) [39]. The arena was sanitized with 70% ethanol between test sessions. Barnes Maze: Spatial memory was assessed on a 91 cm circular platform with 18 holes; one connected to a hidden escape box. After 2 h acclimation, mice underwent four trials/day for four days, with escape latency and errors recorded (VisuTrack). A probe test on day 5 evaluated memory retention. The maze was rotated and cleaned with ethanol between trials [40, 41]. Details are presented in Supplemental Methods. Mouse tissue collection To ensure rigorous control of potential confounders, all sham-operated mice received the same anesthesia regimen as the TBI group (induction with 4% isoflurane, maintenance with 1.5% isoflurane in 100% O₂) and were euthanized at identical time points via cervical dislocation under deep anesthesia, confirmed by absence of pedal reflex. This approach minimized bias from anesthetic or procedural variations, ensuring that observed effects were specifically attributable to TBI [42, 43]. For histological processing, mice were deeply anesthetized with pentobarbital (50 mg/kg, i.p.) and underwent transcardial perfusion with heparinized saline followed by 4% paraformaldehyde. Brains were post-fixed for 24 h, cryoprotected in sucrose gradients, and sectioned at 40 μm thickness. For molecular analyses, saline-perfused brains were microdissected to obtain perilesional tissues, which were flash-frozen and stored at − 80 °C. Additional methodological details are available in the Supplemental Methods. Human brain tissue procurement Formalin-fixed glioma and TBI specimens were obtained with ethical approval and patient consent (Approval No. 2025 − 233, Project Title: Study on Protein Expression, Glial Cell Function, and Gene Expression Changes in Injured Tissues of Patients with Different Types of Brain Injury; General Hospital of the Northern Theater Command, PLA China). Tissues underwent fixation in formalin for 48 h, processed through a graded ethanol and xylene dehydration series, and cryosectioned at 20 μm for archival storage at −80 °C. Detailed procedures are described in the Supplemental Methods. Detailed information about the human patients included in this study is provided in Supplementary Table 1. Reverse transcription quantitative PCR Total RNA was isolated from tissue homogenates with TRIzol reagent (Vazyme, R411) per the manufacturer’s instructions. After removing genomic DNA, cDNA was synthesized. For qRT - PCR, cDNA was mixed with primers, master mix, and water, and the reaction was run utilizing an Applied Biosystems real - time PCR system. Melting curve analysis was used to confirm primer specificity, and relative gene expression was calculated using the 2⁻ΔΔCt method with data from independent biological samples. Details are presented in Supplemental Methods. Primer sequences are listed in Supplemental Tables. Western blot analysis Combined homogenate of cortical (CTX) and hippocampal (HP) tissues from mouse brain were homogenized in ice-cold RIPA lysis buffer (Beyotime Biotech) containing 1× protease inhibitor cocktail. Lysates were subjected to sonication (3 cycles of 5-second bursts at 30% amplitude, with 10-second intervals on ice) and centrifuged at 12,000 rpm for 30 min at 4 °C. Protein concentrations were determined using a bicinchoninic acid (BCA) assay kit (Dingguo Biotech). Equal protein aliquots (30 µg per lane) were separated electrophoretically on 10% SDS-polyacrylamide gels and transferred onto PVDF membranes (Millipore). Membranes were blocked with 5% non-fat dried milk, then incubated with primary antibodies overnight at 4 °C. After TBST washes, membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:10,000 dilution) for 2 h at room temperature. Immunoreactive bands were visualized using an enhanced chemiluminescence (ECL) detection system, and band intensities were quantified with ImageJ software (NIH) after normalization to β-actin. Details are described in the Supplemental Methods. Antibody specifications are listed in Supplemental Tables. Immunohistochemistry Preparation of tissues from fixed or fresh-frozen brains for sectioning, immunofluorescence staining, and confocal image capture was performed following standard protocols [24]. Details, antibody lists, and image analyses are provided in the Supplemental Methods and Supplemental Table 4. Golgi staining Hippocampal dendritic spines were visualized via the FD Rapid GolgiStain Kit (FD NeuroTechnologies) per the manufacturer’s instructions. Brains were impregnated in Solutions A/B (14 days), sectioned at 100 μm, and developed using Solutions D/E. After dehydration and mounting, dendritic segments (> 50 μm from soma) were imaged with a 60× oil immersion objective on a confocal microscope. Spine morphology was classified into thin, mushroom, stubby, and filopodia types based on established ultrastructural criteria, with ≥ 10 dendrites per mouse analyzed by two blinded investigators [44, 45]. Details are presented in Supplemental Methods. Inter-rater reliability assessment Inter-rater reliability was assessed to ensure the objectivity and consistency of the quantitative morphological data obtained by two independent, blinded raters. Following a joint training session to establish stringent morphological criteria for spine classification based on established literature, both raters, who were blinded to the experimental groups (SHAM, TBI + AS-Ctrl, TBI + AS-SIRT1), independently counted the different dendritic spine types (filopodia, long thin, thin, stubby, mushroom, branched) from the same set of high-resolution hippocampal neuron images. The agreement for continuous spine count data was statistically quantified using a two-way random-effects model for absolute agreement, intraclass correlation coefficient (ICC (2,1)), which provides a measure of absolute consistency single measurements. Bland-Altman analysis was further employed to visually assess the agreement and identify any systematic bias by plotting the mean of the two raters’ counts against their difference, with the mean bias and 95% limits of agreement calculated. All statistical analyses were performed using GraphPad Prism (version 9.0 or later). Similar reliability analyses were conducted for all spine types (long thin, thin, stubby, mushroom, branched), all showing comparable or superior agreement levels, available in Supplementary Materials-ICC and Bland-Altman analysis. Enzyme-linked immunosorbent assay (ELISA) MEGF10 levels in membrane fractions isolated from hippocampus of mice were quantified using a commercial ELISA kit (EIAab, Catalog #E3888m) following the manufacturer’s instructions. Membrane proteins were extracted with a specialized commercial kit (Beyotime Biotech, Catalog #P0033). All standards and samples were assayed in duplicate. Absorbance was measured at 450 nm, and sample concentrations were determined by interpolation from a standard curve included in each assay. Additional methodological details are provided in the Supplemental Methods. Primary astrocyte isolation Hippocampal astrocytes were isolated from P0–P3 C57BL/6J mice by aseptic dissection under a stereomicroscope, followed by meningeal removal to minimize non-neuronal contamination. The minced tissues were digested with 0.25% trypsin-EDTA at 37 °C for 10 min, terminated with DMEM supplemented with 10% FBS, and gently triturated using a fire-polished Pasteur pipette. The cell suspension was filtered through 100 μm and 40 μm strainers, plated on poly-L-lysine-coated T-25 flasks at 2 × 10⁵ cells/cm², and maintained at 37 °C with 5% CO₂. Medium was replaced every 72 h, and microglial depletion was achieved by orbital shaking (260 rpm, 18 h) at 7–10 days post-isolation. Yielded > 92% GFAP⁺ astrocytes as confirmed by immunofluorescence [46, 47]. Details are presented in Supplemental Methods. In vitro astrocyte treatment Primary astrocytes were planted into 6-well plates at a density of 1 × 105 cells per well and cultured in serum-reduced DMEM medium. After a 24- hour of adhesion period, cells were treated with recombinant murine IL-1β (R&D, 201-LB-005), diluted in serum-reduced DMEM to a final concentration of 1 ng/mL, and incubated for an additional 24 h [24]. Cell viability remained above 95% throughout the treatment period as determined by trypan blue exclusion assay. Detailed procedures for cell culture and treatment are described in the Supplemental Methods. In vitro viral transduction and plasmid transfection Astrocytes at 70% confluence were transduced with SIRT1-lentivirus or transfected with ATG7 plasmid using Lipofectamine 8000/MEGF10 plasmid using Lipofectamine 3000. Transduction efficiency (> 80%) was verified by fluorescence imaging and Western blot 48–72 h post-treatment. Details are presented in Supplemental Methods. For plasmid transfection, primary astrocytes were cultured to 70–80% confluence. Transfection was performed using Lipo8000™ Transfection Reagent for the ATG7 shRNA plasmid or Lipofectamine 3000 for the MEGF10 plasmid, following the manufacturers’ instructions. Transfection efficiency, consistently exceeding 80%, was assessed by fluorescence imaging (where applicable) and Western blot analysis at 48–72 h post-transfection. Specific protocols for mixture preparation and incubation are provided in the Supplemental Methods. Pharmacological inhibitor treatments To probe specific pathways and molecular mechanisms underlying astrocyte-mediated synaptic phagocytosis and autophagy regulation, primary hippocampal astrocytes were treated with inhibitors prior to IL-1β stimulation (ensuring pathway inhibition precedes inflammation). 3-Methyladenine (3-MA, autophagy inhibitor): From Targetmol (Cat# T1879), 1 mM stock in complete medium (5.96 mg/40 mL, sterile-filtered); applied for 12 h [48]. MG132 (proteasome inhibitor): From Targetmol (Cat# T2154), 1 mM stock in DMSO (1 mg/2.1 mL); used at 50 µM for 4 h [49]. Chloroquine (CQ, lysosomal inhibitor; Targetmol T8689): 1 mM stock in DMSO (1 mg/3.1 mL); applied at 50 µM for 2 h. All treatments followed manufacturer protocols and literature [49], with vehicle controls confirming specificity and > 95% cell viability. Phagocytosis assay After viral transduction and plasmid transfection, the hippocampal astrocytes at 70–80% confluence in 35 mm dishes were incubated with FITC-conjugated particles (1:500 dilution from 10 mg/mL stock) in DMEM with 10% BSA for 6–8 h at 37 °C/5% CO2. Cells were fixed with 4% PFA for 30 min, washed with cold PBS, and stored in PBS with 0.02% sodium at 4 °C. Phagocytosis was quantified by counting internalized fluorescent particles per cell with Trypan Blue quenching and pHrodo-green using confocal microscopy (Supplementary Fig. 3). pHrodo™ Green (Thermo Fisher Scientific, P36013) reagent was reconstituted in DMSO to prepare a 2 mM stock solution (100 µg in 50 µL). For in vitro assays [50], a working concentration of 5 µM was prepared by diluting 2.5 µL stock into 1 mL complete medium. Primary astrocytes were incubated with this solution at 37 °C, and phagocytosis was assessed via fluorescence microscopy at 0-, 1-, and 8-hours post-treatment. All steps were performed under sterile conditions. All analyses were conducted under fully blinded conditions: image files were randomly coded by an independent researcher not involved in quantification to conceal group identities; ROI selection, threshold setting, and 3D model generation were performed using the same parameters across all groups—parameters determined a priori based on negative controls (i.e., FITC-free and unstained samples); and once surfaces were generated, the internalization criteria described above were automatically applied by the software, thereby eliminating observer bias in classification. Details are presented in Supplemental Methods. TUNEL staining Supernatants from treated mouse astrocytes were added to HT22 hippocampal neuronal cells and cultured for 24 h. Cells were fixed with 4% PFA for 20–30 min at room temperature, rinsed three times with PBS (5 min per wash), and permeabilized using 0.3% Triton X-100 for 3–5 min at room temperature followed by PBS washes. TUNEL staining was carried out with a commercial kit following the manufacturer’s instructions, with fresh reagents prepared and handled in the dark. Details are presented in Supplemental Methods. Image acquisition and analysis Fluorescence imaging was conducted on an Olympus FV3000 confocal microscope or Nikon TIRF system. Hippocampal regions adjacent to lesions were imaged at ×60 magnification with z-stacks (GFAP/MEGF10: 15 slices at 1 μm; PSD95/SYP: 20 slices at 2 μm; PSD95/GFAP: 20 slices at 2 μm). 3D reconstructions were created with Imaris software 9.9.0 (Bitplane). Synaptic engulfment was quantified by analyzing PSD95 colocalization within astrocytes using Imaris software, normalized to astrocyte volume. Dendritic spines in 100-µm sections were manually classified into immature (Thin, Long Thin, Filopodia) and mature (Branched, Mushroom, Stubby) by blinded investigators. Image processing included background subtraction and thresholding in ImageJ, with standardized z-stack parameters across all samples. Details are presented in Supplemental Methods. Statistics Statistical evaluations were conducted with GraphPad Prism 8 (GraphPad Software). All datasets were tested for normality using the Shapiro-Wilk test prior to parametric analyses, and outliers were identified and removed using the Grubbs’ test (alpha = 0.05) to ensure robust and unbiased statistical comparisons. For two-group comparisons, unpaired two-tailed t-tests were used; for multi-group comparisons, one-way ANOVA with Bonferroni’s post hoc test or repeated-measures ANOVA were applied. Data are presented as mean ± SEM. Sample sizes (n) represent biologically independent replicates (e.g., individual mice or tissue samples). Blinding was implemented for behavioral scoring and histological analyses. Statistical significance was defined as P < 0.05. Results SIRT1 expression is downregulated in both mice and patients following TBI We initially evaluated the mRNA expression profiles of all seven sirtuin family members (Sirt1–Sirt7) at 3 days post-TBI. This analysis revealed a significant downregulation of Sirt1 mRNA and Sirt3 mRNA in the TBI group compared to sham-operated (SHAM) controls (Fig. 1A). To validate changes at the protein level, Western blot analysis of cerebral cortex (CTX) and hippocampus (HP) was conducted at different time points (Supplementary Fig. 1). Consistent with the mRNA data, SIRT1 protein level was specifically reduced at 3 days in TBI mice, whereas SIRT3 protein levels showed no significant alteration (Fig. 1B and C). Furthermore, immunofluorescent (IF) analysis of brain sections from mice and patients further corroborated SIRT1 downregulation. Specifically, SIRT1 levels in the HP and CTX were significantly lower in TBI mice than in SHAM controls (Fig. 1D and E), and analogous results were observed in cortical tissues of TBI patients compared with glioma controls (Fig. 1F and G). Double immunofluorescence staining indicated significantly reduced SIRT1 expression and decreased colocalization of SIRT1⁺ cells with neuronal (NeuN⁺) or astrocytic (ALDH1L1⁺/GFAP⁺) markers in TBI patients (Fig. 1H and I). Collectively, these data demonstrate consistent SIRT1 downregulation in both TBI mouse models and human patients, suggesting that SIRT1 may serve as a critical molecular mediator in TBI pathogenesis. Reduced SIRT1 expression in mice and patients after TBI. Wild-type (WT) mice were analyzed at 3 days post-TBI (A–E). A RT-qPCR: Sirt1-Sirt7 mRNA in SHAM and TBI mice, normalized to actin (n = 4–5 mice). B and C Western blot images and quantification of SIRT1 and SIRT3 protein levels in SHAM and TBI group (n = 5 mice). D and E Representative IF images and bar graph of SIRT1 (green) in the HP and CTX of mice (n = 6 mice). Nuclei: DAPI (blue). F and G IF staining and quantification of SIRT1 (green) in the CTX of glioma patients (Ctrl) and TBI patients (n = 3 per group). Nuclei: DAPI (blue). H and I IF staining and bar graph of SIRT1 (green) and NeuN (red)/ALDH1L1 (red)/GFAP (red) in the CTX of Ctrl and TBI patients (n = 3 per group). Scale bars: 20 μm (D、F and I). Data: mean ± SEM; 2-tailed, unpaired t-test. *P < 0.05; **P < 0.01; ***P < 0.001. ns = no significance. Data shown are from one representative experiment out of three independent replicates Astrocyte-specific SIRT1 overexpression in the HP mitigates neuronal loss and cognitive deficits after injury To investigate the pathological roles of SIRT1 in TBI, we first examined the cell type-specific localization of SIRT1 in the HP of mice. IF analysis revealed that TBI induced a significant reduction in SIRT1 expression specifically within GFAP⁺ astrocytes in the HP (Fig. 2A). Quantitative analysis revealed that SIRT1⁺ cells within GFAP⁺ astrocytes underwent the most severe reduction in TBI mice compared to the SHAM group, establishing astrocytes as the primary cellular locus of injury-triggered SIRT1 downregulation (Fig. 2B). To explore the functional significance, we generated astrocyte-specific SIRT1-overexpressing mice in the HP by delivering adeno-associated virus (AAV) vectors into Aldh1l1CreERT2/+ transgenic mice (Fig. 2C). IF analysis confirmed a significant upregulation of SIRT1 protein in both ALDH1L1⁺ and GFAP⁺ astrocytes of TBI mice with astrocyte-specific SIRT1 overexpression (TBI + AS-SIRT1) compared with littermate controls (TBI + AS-Ctrl) (Fig. 2D). Astrocytic SIRT1 overexpression attenuates TBI-induced neuronal loss and cognitive dysfunction. WT mice were analyzed at 3 days post-TBI (A). Aldh1l1CreERT2/+ mice were analyzed at 3 days (D) and 21 days (H) post-TBI. A and B IF staining and quantification of SIRT1 (green) and NeuN (red)/GFAP (red)/IBA-1 (red) in the HP of mice (n = 5 mice). Nuclei: DAPI (blue). Scale bar: 20 μm. Insets present enlarged views of regions indicated by white dotted rectangles, scale bar: 5 μm. C Schematic illustration of the experimental timeline: virus injection, TBI modeling, tamoxifen injection, IF and behavioral tests (Barnes Maze and OFT). D Representative confocal images and quantification of SIRT1 (blue) and ALDH1L1/GFAP (red) expression in the HP of Aldh1l1CreERT2/+ mice post-TBI, injected with control virus (TBI + AS-Ctrl) or SIRT1 overexpression virus (TBI + AS-SIRT1) (n = 7 mice). Scale bars: 20 μm. Enlarged views show details, Scale bars: 5 μm. E Representative heatmaps of mouse travel paths in the Barnes Maze. F Quantification of escape latency in the two groups (n = 7 mice). G Quantification of traveled distance, error number, and mean velocity (n = 7 per group). H and I IF staining and bar graph of NeuN⁺ neurons (red) in the HP at Day 0 (Pre-TBI) and Day 21 after injury (n = 7 mice). Scale bar: 20 μm. Data: mean ± SEM. Escape latency across Barnes Maze training days was analyzed using a ​​linear mixed-effects model​​ with Group (TBI + AS-Ctrl, TBI + AS-SIRT1) and Time (Days 1–5) as fixed effects, Mouse ID as a random effect, and an unstructured covariance matrix. Post hoc comparisons used ​​Bonferroni correction​​. 2-tailed, unpaired t-test for others. *P < 0.05; **P < 0.01; ***P < 0.001. ns = no significance. Data shown are from one representative experiment out of three independent replicates Behavioral assessments using the Barnes Maze and Open Field Test showed that TBI + AS-SIRT1 mice exhibited a progressive decrease in escape latency during the Barnes Maze acquisition phase, maintaining low latency from training day 4 onward (Fig. 2E and F). These mice also traveled a shorter total distance, made fewer navigational errors, and maintained comparable mean velocity, collectively demonstrating improved learning capacity relative to controls (Fig. 2G). The Open Field Test revealed no significant intergroup differences (Supplementary Fig. 1), thereby ruling out motor function impairment as a confounding factor. Confocal microscopy at 21 days post-injury showed a significant restoration of neuronal count and NeuN expression in astrocyte-specific SIRT1-overexpressing mice compared with controls (Fig. 2H and I). Collectively, these findings demonstrate that astrocyte-targeted SIRT1 overexpression mitigates hippocampal neuronal loss and ameliorates spatial learning and memory in a TBI model. Astrocyte-specific SIRT1 overexpression ameliorates dendritic spine density reduction and synaptic loss in hippocampal neurons after TBI TBI triggers complex pathological cascades, including apoptosis, inflammation, and synaptic remodeling in the hippocampus—key targets for alleviating TBI-associated cognitive deficits. We investigated the role of astrocytic SIRT1 in maintaining dendritic spine integrity using Golgi-Cox staining at 21 days after injury (Fig. 3A). Quantification of dendritic spine subtypes on secondary dendrites (categorized as mature spines: mushroom, stubby, branched; and immature spines: filopodia, long thin, thin) revealed distinct changes (Fig. 3B and C). Based on the quantitative analysis of dendritic spine density, TBI + AS-SIRT1 mice exhibited a significant enhancement in mature spine morphology compared to TBI + AS-Ctrl groups: mushroom spine density increased approximately 2-fold (reaching ~ 4 spines/10µm), stubby spines rose by ~ 1.5-fold, and branched spines—which were nearly absent in the TBI group—showed clear recovery, while filopodia, long thin, and thin spines remained unchanged. These findings underscore the critical role of astrocytic SIRT1 in promoting and maintaining mature dendritic spine architecture after TBI. Dual-labeling of presynaptic marker synaptophysin (SYP) and postsynaptic marker discs large MAGUK scaffold protein 4 (PSD95) showed that TBI + AS-SIRT1 mice had higher densities of SYP⁺ presynapses, PSD95⁺ postsynapses, and SYP⁺/PSD95⁺ co-localized synapses compared to the TBI + AS-Ctrl mice (Fig. 3D and E). Western blot analysis of synaptic markers SYP and PSD95 in the hippocampal region of the lesioned side confirmed that astrocytic SIRT1 overexpression significantly upregulated their protein levels in TBI + AS-SIRT1 mice (Fig. 3F and G). These results demonstrate that astrocyte-specific SIRT1 overexpression attenuates dendritic spine loss and synaptic degeneration in hippocampal neurons after TBI, implying a mechanism whereby astrocytic SIRT1 alleviates TBI-induced cognitive deficits by preserving spine density and synaptic integrity, as evidenced by the restoration of mature spine subtypes and upregulation of synaptic markers. Astrocytic SIRT1 overexpression mitigates TBI-induced dendritic spine deficits and synaptic impairments in hippocampal neurons. Aldh1l1CreERT2/+ mice were analyzed at 21 days post-TBI. A Representative Golgi staining images of dendritic spines on secondary dendrites in hippocampal neurons (n = 5 mice). Scale bar: 100 μm. B Bar graph of dendritic spine morphologies in immature (Thin, Long Thin, Filopodia) and mature (Branched, Mushroom, Stubby) categories. The graph depicts the percentage distribution of distinct spine morphologies. C Quantitative analysis of spine density across filopodia, long thin, thin, stubby, mushroom, and branched spine types. Data derived from 10, 12, and 12 slices in SHAM, TBI, and TBI + AS-SIRT1 groups respectively (n = 4–5 mice, 4 sections/mouse). D and E Representative confocal images and quantitative analysis of PSD95 (green) and SYP (red) immunostaining in the HP of mice (n = 5–7 mice). Scale bar: 20 μm. Insets show enlarged views of the white dotted rectangle regions (scale bar: 20 μm), including three-dimensional volume renderings to visualize spatial distribution. F and G Western blot images and bar graph of PSD95 and SYP levels in HP of mice (n = 6 mice). Data reflect protein expression normalized to actin. Data: mean ± SEM. One-way ANOVA followed with Bonferroni’s post hoc test. *P < 0.05; **P < 0.01; ***P < 0.001. Data shown are from one representative experiment out of three independent replicates Astrocytic SIRT1 overexpression alleviates astrogliosis and reduces synaptic phagocytosis after brain injury GFAP immunostaining was performed to evaluate the effect of astrocyte-specific SIRT1 overexpression on astrogliosis. As shown in Fig. 4A, astrocytes in the TBI + AS-Ctrl mice displayed robust reactive astrogliosis, characterized by hypertrophic processes, shortened arborizations, and enlarged soma. By contrast, TBI + AS-SIRT1 mice exhibited significant attenuation of astrocyte reactivity. Morphometric analysis confirmed these observations: compared with TBI + AS-Ctrl mice, TBI + AS-SIRT1 mice exhibited increased astrocyte solidity, reduced cellular perimeter, a lower number of GFAP⁺ astrocytes and a smaller GFAP-positive area percentage (Fig. 4B). Astrocytic phagocytic ability was assessed by quantifying intracellular FITC puncta. Following intrahippocampal injection of FITC into the lesioned hemisphere, confocal Z-stack imaging (threesided mode) and Imaris-based 3D reconstruction (local magnification) revealed that activated astrocytes in the TBI + AS-Ctrl mice phagocytosed more FITC-labeled puncta (appearing as reddish to darker red hues in 3D reconstruction local magnification, Fig. 4C). Co-localization assays of FITC and GFAP in astrocytes revealed a significant positive correlation between astrocytic phagocytosis of FITC-labeled particles—quantified by the cumulative volume and mean intensity of intracellular FITC puncta—indicating an excessive phagocytic state in astrocytes of TBI + AS-Ctrl mice. Notably, astrocyte-specific SIRT1 overexpression effectively mitigated this enhanced FITC phagocytosis (Fig. 4E). Co-staining for GFAP and the postsynaptic marker PSD95 further confirmed increased GFAP-PSD95 co-localization in TBI + AS-Ctrl mice, reflecting enhanced synaptic phagocytosis by activated astrocytes, which was notably reduced in TBI + AS-SIRT1 mice (Fig. 4D). Quantitative analysis of intracellular PSD95 puncta cumulative volume and mean intensity revealed that activated astrocytes in TBI + AS-Ctrl mice exhibited higher cumulative volume of intracellular PSD95 puncta and greater mean PSD95 intensity—findings confirming that excessive synaptic phagocytosis impairs synaptic integrity. By contrast, astrocyte-specific SIRT1 overexpression preserved synaptic structures, with phagocytosed astrocytes in the TBI + AS-SIRT1 group showing significantly lower mean PSD95 intensity than TBI + AS-Ctrl mice (Fig. 4F). Collectively, these findings demonstrate that astrocyte-specific SIRT1 overexpression serves as a key regulatory mechanism, effectively alleviating astrogliosis, suppressing synaptic phagocytosis, and maintaining synaptic integrity after brain injury. Astrocytic SIRT1 overexpression alleviates TBI-induced astrogliosis and synaptic phagocytosis. Aldh1l1CreERT2/+ mice were analyzed at 3 days (A-C) and 21 days (D) post-TBI. A Representative immunostaining images of GFAP (red) in HP of mice. Nuclei: DAPI (blue). Scale bar: 20 μm. Insets display enlarged views of white dotted rectangle-marked areas and Imaris 3D renderings to highlight activated astrocyte morphological features. Scale bar: 5 μm. B Quantitative analyses of astrocyte solidity, perimeter, GFAP⁺ cell number, and GFAP intensity (n = 21 cells from 7 mice or n = 7 mice); (C) Representative immunostaining images of GFAP (red) and FITC (green) in HP of mice. Scale bar: 20 μm. Based on the “Overlap Volume Ratio to Surface” metric, the color scheme is defined as follows: blue-to-purple hues represent low ratio values (0.000–0.5), indicating puncta located externally or adherent to the astrocyte surface, while orange-to-red hues correspond to high ratio values (0.5–0.961), signifying fully internalized (phagocytosed) puncta. This quantitative analysis was performed using Imaris 9.9. Insets provide magnified views of regions marked by yellow-dotted rectangles, with Imaris 3D renderings highlighting astrocyte-internalized FITC puncta. Scale bar: 5 μm. D Representative immunostaining images of GFAP (red) and PSD95 (green) in HP of mice. Scale bar: 20 μm. Middle panels display Imaris-based 3D reconstructions of astrocytes, illustrating PSD95 distribution: blue-purple signals indicate PSD95 distal to the astrocyte surface, while orange-red signals denote internalized (phagocytosed) PSD95 puncta. Insets show enlarged views of the yellow-dotted rectangle regions, with Imaris 3D renderings emphasizing astrocyte phagocytosed PSD95 puncta. Scale bar: 5 μm. E and F Quantitative analyses of FITC and PSD95 puncta internalized by astrocytes (n ≥ 12 cells from 5 mice). Data: mean ± SEM. One-way ANOVA followed with Bonferroni’s post hoc test. *P < 0.05; **P < 0.01; ***P < 0.001 SIRT1 modulates MEGF10 expression in astrocytes after brain injury, linking to synaptic phagocytosis regulation To dissect the mechanism through which astrocytic SIRT1 regulates synaptic phagocytosis, we first screened astrocytic phagocytic receptors. As summarized in Fig. 5A, receptors such as MEGF10, MERTK, and others are implicated in astrocytic phagocytosis. Gene expression analysis revealed that among these, Megf10 expression exhibited a significant correlation with SIRT1 (Fig. 5B). Analysis of GDS5612 dataset from mouse hippocampal neural stem cells/neural progenitor cells treated with DMSO or resveratrol (a SIRT1 agonist) further showed that Megf10 was the one of the molecules whose mRNA expression decreased following resveratrol treatment, identifying Megf10 as a pivotal target (Fig. 5C). Western blot analysis of the lesioned hippocampal region demonstrated that MEGF10 protein levels were elevated in TBI + AS-Ctrl mice compared with SHAM mice. Notably, TBI + AS-SIRT1 mice showed a significant reduction in MEGF10 expression (Fig. 5D and E). Immunofluorescence co-staining corroborated these findings: TBI enhanced MEGF10 co-localization with GFAP⁺ astrocytes, an effect attenuated by SIRT1 overexpression (Fig. 5, F and G). ELISA quantification of the lesioned hippocampal region revealed significantly elevated MEGF10 protein levels in TBI + AS-Ctrl mice compared to SHAM, while astrocyte-specific SIRT1 overexpression markedly attenuated MEGF10 expression (Fig. 5H). In vitro, treatment of primary hippocampal astrocytes with Interleukin-1 beta (IL-1β) (to mimic post-TBI injury induced astrocyte reactivity) upregulated MEGF10 expression. Confocal microscopy revealed that IL-1β induction significantly increased MEGF10 expression in both the plasma membrane and cytoplasm of astrocytes (Fig. 5I and J). Total internal reflection fluorescence (TIRF) microscopy—a technique enabling precise quantification of plasma membrane protein expression—confirmed that IL-1β induced increased MEGF10 expression and clustering at the cell membrane (Fig. 5I and J). Conversely, SIRT1 overexpression diminished MEGF10 membrane localization and clustering. Western blot analysis further confirmed that IL-1β upregulated MEGF10 in astrocytes, an effect suppressed by SIRT1 overexpression (Fig. 5K). Collectively, these findings highlight the critical role of the SIRT1–MEGF10 axis in mitigating astrocyte-mediated synaptic loss. By modulating MEGF10 expression, SIRT1 directly regulates synaptic phagocytosis, linking synaptic structure preservation to reduced glial activation. This mechanism underscores that astrocyte-specific SIRT1 overexpression safeguards synaptic integrity by regulating phagocytic receptor expression after brain injury. SIRT1 modulates MEGF10 expression in astrocytes under in vivo and in vitro brain injury conditions. Aldh1l1CreERT2/+ mice were analyzed at 3 days (D-H) post-TBI. A Table summarizing astrocytic phagocytic receptors (including MEGF10, MERTK, ABCA1, among others), with their corresponding regulatory pathways and reference citations. B Relative mRNA expression levels of astrocytic phagocytic receptors in primary mouse hippocampal astrocytes, comparing the Ctrl group (transfected with empty vector) and SIRT1 group (transfected with SIRT1 overexpression vector), n = 3 independent experiments. C Analysis of mRNA expression in the GDS5612 dataset, derived from mouse hippocampal neural stem cells/neural progenitor cells treated with DMSO or resveratrol (a SIRT1 agonist). D and E Western blot images and bar graph of MEGF10, MERTK, ABCA1, GULP1, and LRP1 in HP of SHAM, TBI + AS-Ctrl, and TBI + AS-SIRT1 mice (n = 6 mice). F and G Immunofluorescence co-staining images of GFAP (green), MEGF10 (red), and DAPI (blue) with quantification in HP of TBI + AS-Ctrl and TBI + AS-SIRT1 mice (n = 6–7 mice). Scale bar: 20 μm. Enlarged views highlight the detailed co-localization of MEGF10 with astrocytes. Scale bar: 5 μm. H Quantitative ELISA results for MEGF10 protein expression in HP of each group (n = 3 mice). I - K Primary mouse astrocytes were transfected with empty vector or SIRT1 overexpression vector, then incubated in the absence (Control) or presence of IL-1β for 24 h, designated as the Ctrl (empty vector, no IL-1β), IL-1β + Vector (empty vector + IL-1β), and IL-1β + SIRT1 (SIRT1 overexpression vector + IL-1β) groups. I and J Immunostaining images and quantitative analysis using confocal and TIRF microscopy, showing GFAP (green), MEGF10 (red), and DAPI (blue) in cultured primary astrocytes from Ctrl, IL-1β + Vector, and IL-1β + SIRT1 groups (n = 3–5 independent experiments). Scale bar: 5 μm. K Western blot analysis and quantification of MEGF10 protein levels from Ctrl, IL-1β + Vector, and IL-1β + SIRT1 groups (n = 3 independent experiments). All data are presented as the mean ± SEM. One-way ANOVA followed with Bonferroni’s post hoc test; *P < 0.05; **P < 0.01; ***P < 0.001 SIRT1 exerts protective effects by modulating MEGF10-mediated astrocytic phagocytosis and neuronal apoptosis, primarily through promoting autophagic clearance of the MEGF10 receptor To validate the functional interplay among SIRT1, MEGF10, astrocytic phagocytosis, and neuronal survival, in vitro experiments were conducted using primary hippocampal astrocytes from neonatal mice. As illustrated in the schematic (Fig. 6A), astrocytes were incubated with FITC-labeled fragments; astrocytic phagocytosis and subsequent transport to lysosomes for degradation were assessed by examining the percentage of FITC-positive area within astrocytes and colocalization of FITC with a major lysosomal marker: Lysosomal-associated membrane protein 2 (LAMP2). IF analysis revealed that IL-1β induction increased the percentage of FITC-positive area within astrocytes; furthermore, minimal colocalization of FITC with LAMP2 was noted, indicating enhanced astrocytic phagocytosis but inefficient lysosomal degradation via autophagy. In contrast, SIRT1 overexpression significantly reduced the FITC-positive area and markedly increased FITC-LAMP2 colocalization, reflecting that SIRT1 not only suppressed phagocytic capacity but also promoted efficient lysosomal degradation of phagocytosed FITC, thereby preventing intracellular accumulation. Conversely, co-overexpression of SIRT1 and MEGF10 (SIRT1 + MEGF10 group) reversed these effects: the FITC-positive area increased, and FITC-LAMP2 colocalization decreased, indicating restored phagocytosis of FITC and impaired lysosomal degradation (Fig. 6B, E). For assessing neuronal apoptosis, supernatants from astrocyte cultures were applied to hippocampal neurons (Fig. 6C). TUNEL staining revealed that the supernatant from the IL-1β + Vector group significantly induced neuronal apoptosis, whereas overexpression of SIRT1 decreased the number of TUNEL-positive neurons. Co-overexpression of MEGF10 attenuated the protective effect of SIRT1 (Fig. 6D, F), highlighting the pivotal role of the SIRT1–MEGF10 axis in regulating astrocytic phagocytosis and neuronal survival after injury. SIRT1 modulates MEGF10 expression in astrocytes via enhancing autophagy rather than the ubiquitin-proteasome system. A Schematic diagram illustrating the assessment of astrocytic phagocytosis through uptake of FITC-labeled fragments. B Confocal images of primary astrocytes in Ctrl, IL-1β + Vector, IL-1β + SIRT1, and IL-1β + SIRT1 + MEGF10 groups, showing FITC (green), LAMP2 (red) and DAPI (blue) staining. Scale bar: 60 μm. Insets show enlarged views of white-dotted rectangle regions. Scale bar: 5 μm. C Schematic diagram depicting the collection of conditioned media from differentially treated astrocytes and its application to HT22 hippocampal neurons. D TUNEL staining for assessing neuronal apoptosis in Ctrl, IL-1β + Vector, IL-1β + SIRT1, and IL-1β + SIRT1 + MEGF10 groups. Images show TUNEL positive cells (green), DAPI (blue), and merged channels. Scale bar: 50 μm. E Quantitative analysis of the percentage area covered by FITC puncta and colocalization of FITC and LAMP2. F Quantitative analysis of TUNEL-positive neurons. G Confocal images of primary astrocytes in Ctrl, IL-1β + Vector, IL-1β + SIRT1, and IL-1β + SIRT1 + 3-MA (3-methyladenine, an autophagy inhibitor) groups, showing MEGF10 (blue) and LC3 (red). Scale bar: 20 μm. Insets show enlarged views of white dotted rectangle-marked areas. Scale bar: 5 μm. H and I Western blot images and bar graph of LC3, P62, BECLIN1, MEGF10, and SIRT1 protein levels in primary astrocytes. Data: mean ± SEM (at least 3 independent experiments). One-way ANOVA followed with Bonferroni’s post hoc test; *P < 0.05; **P < 0.01; ***P < 0.001 To explore the underlying regulatory mechanism, we investigated autophagy and the ubiquitin-proteasome system (UPS). Using the autophagy inhibitor 3-Methyladenine (3MA), analysis of autophagy-related proteins (LC3-II/LC3-I ratio, BECLIN1, P62) confirmed inhibited autophagy; 3MA treatment increased MEGF10 expression without affecting SIRT1 (Supplementary Fig. 5A). To further clarify the relationship between MEGF10 and autophagy induction, IF staining confirmed that in the Ctrl group, MEGF10 expression was low, with most MEGF10 colocalizing with LC3 (a key marker of autophagy). However, in the IL-1β + Vector group, MEGF10 expression was increased, with minimal colocalization with LC3. Following SIRT1 overexpression, MEGF10-LC3 colocalization was promoted, while autophagy inhibition reversed these effects of SIRT1 (Fig. 6G). These findings were further validated by Western blot analysis (Fig. 6H, I): in IL-1β-treated astrocytes, autophagy was inhibited (as indicated by autophagy-related proteins), and MEGF10 expression was increased. In contrast, SIRT1 overexpression promoted autophagy and decreased MEGF10—an effect reversed by 3MA. Additionally, SIRT1 overexpression enhanced autophagy (evidenced by elevated LC3-II/LC3-I ratio and BECLIN1, and reduced P62), which was abrogated by 3MA. Collectively, these data indicate that in astrocytes, IL-1β induction reduces SIRT1, inhibits autophagy, and increases MEGF10 expression; conversely, SIRT1 overexpression promotes autophagy, thereby decreasing MEGF10 levels—suggesting that SIRT1 modulates MEGF10-mediated astrocytic phagocytosis and neuronal apoptosis primarily by promoting autophagy. Regarding the UPS, Z-Leu-Leu-Leu-al (MG132) treatment under basal condition did not significantly alter MEGF10 or SIRT1 levels (Supplementary Fig. 5B). Co-administration of MG132 with SIRT1 overexpression after IL-1β induction failed to reverse SIRT1-induced reduction of MEGF10 (Supplementary Fig. 5 C). Mechanistically, SIRT1 reduces MEGF10 protein expression primarily via promoting autophagy rather than the UPS, thus clarifying its regulatory specificity in astrocyte-mediated synaptic regulation after brain injury. Astrocyte-specific ATG7 knockdown inhibits autophagy and reverses the beneficial effects of astrocytic SIRT1 overexpression on synaptic phagocytosis and neurological function after TBI Autophagy related 7 (ATG7), a core autophagy regulator, mediates LC3 lipidation (LC3-I to LC3-II) and autophagosome maturation; its depletion disrupts autophagic flux, impairing autophagosome formation and lysosomal fusion. To dissect autophagy’s role in SIRT1-mediated protection with ATG7 (Supplementary Fig. 4), we also established a TBI model with astrocyte-specific SIRT1 overexpression (AS-SIRT1), comparing control scramble shRNA (Scr-shRNA) and astrocyte-targeted ATG7-shRNA (via the GfaABC1D promoter) to deplete ATG7, a critical autophagy regulator (Fig. 7A). Double immunofluorescence confirmed astrocytic ATG7 depletion following ATG7-shRNA delivery, and Western blotting verified reduced ATG7 levels of the lesioned hippocampal region (Fig. 7B and C). To assess autophagy status, Western blotting of autophagy-related proteins in the injured hippocampus revealed that ATG7-shRNA (vs. Scr-shRNA) impaired autophagy, as indicated by a reduced LC3-II/LC3-I ratio (defective LC3 lipidation), downregulated BECLIN1 (suppressed autophagy initiation), and accumulated P62 (blocked autophagic flux; Fig. 7D). To assess synaptic phagocytosis, we analyzed the postsynaptic protein PSD95. Our results indicate that autophagy inhibition blocked the ability of SIRT1 to suppress the astrocytic phagocytic receptor MEGF10. GFAP/PSD95 co-immunofluorescence revealed increased cumulative PSD95⁺ puncta within astrocytes (enhanced synaptic phagocytosis), while Western blotting demonstrated reduced PSD95 and a downward trend in SYP, consistent with accelerated synaptic loss (Fig. 7E and F). Autophagy inhibition via astrocyte-specific ATG7 knockdown reverses the beneficial effects of astrocytic SIRT1 overexpression on synaptic phagocytosis and neurological function after TBI. Aldh1l1CreERT2/+ mice were analyzed at 3 days (B) and 21 days (C-F) post-TBI. A–H Aldh1l1CreERT2/+ mice were injected with virus to upregulate SIRT1 expression in the hippocampus, alongside injection of either Scr-shRNA virus (TBI + AS-SIRT1 + Scr-shRNA) or ATG7-shRNA virus (TBI + AS-SIRT1 + ATG7-shRNA). A Schematic illustration of the experimental timeline: virus injection, TBI modeling, tamoxifen injection, IF/WB and behavioral tests (Barnes Maze and OFT). B Representative confocal images and quantification of ATG7 (blue) and GFAP (magenta) expression in the HP of Aldh1l1CreERT2/+ mice injected with Scr-shRNA virus or ATG7-shRNA virus (n = 7 mice). Scale bars: 20 μm; enlarged views show details, Scale bars: 5 μm. C Western blot images and bar graph of ATG7 in HP (n = 3 mice). D Western blot images and quantification of autophagy-related proteins (LC3, P62, BECLIN1) in the HP (n = 3 mice per group). E Representative immunostaining images and quantitative analysis of GFAP (red) and PSD95 (green) in HP. Scale bar: 20 μm. Based on the “Overlap Volume Ratio to Surface” metric, the color scheme is defined as follows: blue-to-purple hues represent low ratio values (0.000–0.5), indicating puncta located externally or adherent to the astrocyte surface, while orange-to-red hues correspond to high ratio values (0.5–0.961), signifying fully internalized (phagocytosed) puncta. This quantitative analysis was performed using Imaris 9.9. Insets show enlarged views of yellow-dotted rectangle regions, with Imaris 3D renderings highlighting astrocyte-phagocytosed PSD95 puncta (n ≥ 12 cells from 5 mice). Scale bar: 5 μm. F Western blot images and bar graph of MEGF10 and synaptic proteins (SYP and PSD95) in the HP (n = 3 mice). G Representative heatmaps of mouse travel paths in the Barnes Maze. H Quantification of escape latency, traveled distance and mean velocity (n = 5–7 mice). All data are presented as the mean ± SEM from 3 independent experiments. Escape latency across Barnes Maze training days was analyzed using a ​​linear mixed-effects model​​ with Group (TBI + AS-SIRT1 + Scr-shRNA, TBI + AS-SIRT1 + ATG7-shRNA) and Time (Days 1–5) as fixed effects, Mouse ID as a random effect, and an unstructured covariance matrix. Post hoc comparisons used ​​Bonferroni correction​​. 2-tailed, unpaired t-test; *P < 0.05; **P < 0.01; ***P < 0.001; ns = no significance. Data shown are from one representative experiment out of three independent replicates Heatmap analysis (Fig. 7G) revealed distinct spatial search patterns. In the Scr-shRNA group, the heatmap—where color intensity correlated with dwell time—was highly concentrated around the target escape hole, evidenced by the strong signal at the green arrow, reflecting accurate target localization and intact spatial memory. In contrast, the heatmap of the ATG7-shRNA group appeared diffuse and disorganized, with weak signal at the target escape hole, indicative of a disoriented search strategy and severe spatial memory impairment. Additionally, quantitative assessments of escape latency, travel distance, and mean velocity showed that ATG7-shRNA exacerbated cognitive deficits, manifested by prolonged escape latency and increased travel distance, which reversed the protective effects mediated by astrocytic SIRT1 overexpression (Fig. 7H). Collectively, these behavioral measures confirmed that ATG7-shRNA exacerbated cognitive impairments—characterized by prolonged escape latency and increased travel distance—thereby abrogating the protective benefits of astrocytic SIRT1 overexpression. Taken together, astrocytic ATG7 depletion blocks autophagy, impairing SIRT1’s ability to suppress MEGF10-mediated synaptic phagocytosis and hindering neurological recovery after TBI. These findings underscore autophagy as a critical effector pathway underlying the protective functions of astrocytic SIRT1. Discussion TBI-induced cognitive dysfunction arises from intricate pathological interactions among neuronal death, synaptic loss, and neuroglial dysfunction [24–27]. A central question guiding this work is: How do astrocytic functions—particularly their phagocytic activity—regulate synaptic homeostasis and cognitive recovery after TBI? As primary synaptic support cells in the central nervous system (CNS), astrocytes exhibit a dynamic dual role in phagocytosis: they clear damaged synaptic debris to maintain neural network homeostasis under physiological conditions [18, 19, 51] but aberrantly phagocytose functional synapses in pathological states post-TBI, directly exacerbating cognitive impairment [17, 52–57]. Top panel: Behavioral and cellular phenotypes. WT mice post-TBI: Traumatic brain injury (TBI) reduces astrocytic SIRT1, triggering upregulation of the phagocytic receptor MEGF10. Elevated MEGF10 promotes astrocytic engulfment of postsynaptic components (e.g., dendritic spine structures), leading to synaptic degeneration (sparse dendritic spines) and cognitive deficits (reflected by disorganized spatial search patterns in the Barnes Maze, symbolized by the diffuse target zone). Astrocyte-specific SIRT1 overexpression (SIRT1 OE) post-TBI: Forced SIRT1 upregulation in astrocytes suppresses MEGF10 expression, inhibiting astrocytic phagocytosis of postsynaptic proteins. This preserves dendritic spine morphology and synaptic integrity, correlating with improved spatial memory (represented by focused targeting in the Barnes Maze schematic). Bottom panel: Molecular mechanism. WT astrocytes post-TBI: Reduced SIRT1 downregulates ATG7, impairing autophagic flux. Defective autophagy fails to degrade MEGF10, leading to accumulation of MEGF10 and enhanced astrocytic phagocytosis of neuronal synapses. SIRT1 OE astrocytes post-TBI: Increased SIRT1 enhances ATG7-dependent autophagy, promoting MEGF10 degradation. Reduced MEGF10 levels attenuate astrocytic phagocytosis, safeguarding synaptic structures. This study addresses this question by focusing on astrocytic SIRT1, revealing a novel regulatory axis underlying TBI-related cognitive recovery. Core findings demonstrate that (Fig. 8): TBI downregulates astrocytic SIRT1 in wild-type mice, impairing ATG7-dependent autophagy and upregulating the phagocytic receptor MEGF10—triggering aberrant synaptic phagocytosis, synaptic loss, and neurological deficits. Astrocyte-specific SIRT1 overexpression reverses this pathology by enhancing ATG7-mediated autophagy, suppressing MEGF10, preserving dendritic spine morphology (particularly in the hippocampal CA1 region) and synaptic integrity, and ameliorating spatial learning and memory impairments. Mechanistically, SIRT1 degrades MEGF10 via autophagy—not the ubiquitin-proteasome system—defining a regulatory cascade: SIRT1→ATG7-mediated autophagy→MEGF10→astrocytic synaptic phagocytosis. Schematic model illustrating astrocytic SIRT1-mediated protection against TBI-induced synaptic loss via autophagy-dependent regulation of MEGF10 Our data demonstrate that astrocyte-specific SIRT1 overexpression ameliorates TBI-induced astrocytic hyper-phagocytosis, promotes cognitive recovery, and restores synaptic integrity—as evidenced by the recovery of hippocampal dendritic spine density, PSD95 levels, and ​​HOMER1​​ protein expression (Supplementary Fig. 6). Conversely, SIRT1 deficiency is sufficient to evoke excessive synapse phagocytosis by astrocytes and cause behavioral abnormalities in TBI animals. This work, together with previous findings that astrocytes play major roles in adult hippocampal synapse elimination for circuit homeostasis [19], challenges the general Prevailing evidence supports that microglia act as principal synapse-phagocytosing cells regulating synapse abundance in developing and adult brains. The dominance of astrocytes over microglia within this context may arise from their distinct spatiotemporal division of phagocytic functions in CNS pathogenesis: As innate immune cells, microglia rapidly clear apoptotic debris via CD68 antigen (CD68) and triggering receptor expressed on myeloid cells 2 (TREM2) during the acute phase (0–72 h) and dominate inflammatory regulation [58–63]. Microglial MERTK/AXL signaling mediates phagocytosis of apoptotic cells, debris, and dysfunctional synapses to sustain brain homeostasis. Complement mechanisms (e.g., C1q/C3) tag aberrant neural elements for recognition, boosting clearance efficiency via TAM (Tyro3, Axl, MerTK) receptor interactions– a process mediated by Tyro3, Axl, and MerTK receptors that is essential for phagocytic signaling [64–67]. In contrast, astrocytes contribute significantly to synaptic phagocytosis in the chronic phase (≥ 7 days), selectively engulfing synaptic components via MEGF10 and Axl in cognitive brain regions like the hippocampus, thereby directly regulating synaptic remodeling [15, 58, 68, 69]. Using integrated in vitro and in vivo experimental strategies, we establish MEGF10 as a critical phagocytic receptor in astrocytes responding to TBI, aligning with accumulating evidence that astrocytic phagocytosis exerts pivotal functions in brain physiology and behavioral modulation. This is consistent with MEGF10’s established function as a phagocytic receptor mediating synaptic remodeling [17, 18, 51, 56, 70, 71]. This study further confirms that SIRT1’s neuroprotective effect against astrocytic hyper phagocytosis is associated with suppressing MEGF10 expression, suggesting that manipulating phagocytic receptor expression in astrocytes may act as a therapeutic intervention or preventive approach for brain injury. Notably, we unexpectedly found SIRT1 regulates MEGF10 via autophagy—consistent with crosstalk between SIRT1 and autophagy in neurodegenerative contexts [72–76]—rather than the ubiquitin-proteasome system. This challenges the canonical view of SIRT1 as a primarily deacetylase-dependent regulator of proteostasis and reveals a novel post-translational mechanism for phagocytic receptor control. While IL-1β was utilized here as a prototypical inflammatory stimulus, future studies should explore the contributions of other TBI-upregulated cytokines (e.g., TNF-α, IL-6) to astrocytic phagocytosis and synaptic remodeling. While our findings strongly support a primary and pivotal role for astrocytic phagocytosis, mediated by the SIRT1-autophagy-MEGF10 axis, in post-TBI synaptic loss and cognitive deficits, we also acknowledge the potential contributions of other glial cell types within this complex pathological milieu. Microglia, the professional phagocytes of the CNS, are undoubtedly active in the response to neural injury. However, due to the lack of quantitative analysis of IBA1/CD68 colocalization in our study, we cannot definitively rule out secondary changes in microglial activity following astrocytic SIRT1 manipulation. Furthermore, we recognize the emerging concept of significant functional heterogeneity among astrocyte subpopulations. Our study focused on responsive, GFAP-positive astrocytes in the hippocampal CA1 region; whether different astrocytic subtypes or those in other brain regions contribute equally to this phagocytic pathway remains an important question for future investigation. Therefore, within the specific context of our model—utilizing astrocyte-targeted interventions in the chronic phase of TBI—we conclude that the dampening of astrocytic phagocytosis is the dominant mechanism for functional recovery, while incorporating a more nuanced discussion of the broader cellular ecosystem and its heterogeneity. Our findings demonstrate that SIRT1 upregulation enhances autophagic flux, ultimately leading to MEGF10 degradation (Supplementary Fig. 5D and 5E); however, the upstream mechanisms through which SIRT1 initiates autophagy warrant deeper exploration. One compelling pathway involves SIRT1-mediated deacetylation of key autophagy-related proteins, such as ATG5 or ATG7 [77, 78], which may facilitate phagophore expansion and promote autophagosome maturation. Additionally, SIRT1 may activate the AMPK–ULK1 signaling axis—by deacetylating and activating AMPK [79], SIRT1 could induce ULK1 phosphorylation at Ser317, thereby initiating autophagy. These hypothetical pathways are strongly supported by our empirical data, which show that SIRT1-driven reduction of MEGF10 is abolished upon ATG7 knockdown or lysosomal inhibition, providing an integrated mechanism linking SIRT1’s deacetylase function to autophagic degradation of MEGF10. These insights not only elucidate potential nodes for therapeutic intervention in TBI and related neurodegenerative disorders but also suggest that precision targeting of autophagy—e.g., via ATG7-specific modulation—may minimize off-target effects associated with broad autophagy regulators, offering a safer therapeutic strategy for TBI. Furthermore, interventions for chronic TBI should prioritize astrocyte-specific pathways over pan-glial or neuronal targets, highlighting the need for cell-type-specific delivery systems, such as ALDH1L1-driven vectors. The SIRT1–ATG7–MEGF10 axis may represent a conserved regulatory module across conditions involving aberrant synaptic phagocytosis, including Alzheimer’s disease and epilepsy, thereby providing a unified framework for understanding glial-mediated synaptic dysfunction across neurological diseases. Our results also advance traditional models focused on neurotransmitter regulation or metabolic support as primary astrocyte-neuron interactions by identifying phagocytic regulation via SIRT1-autophagy as a novel, active mechanism through which astrocytes control synaptic integrity, enriching our understanding of bidirectional communication. While SIRT1 was previously viewed as a modulator of the ubiquitin-proteasome system for protein degradation, our data expand its role to include autophagy-mediated targeting of specific receptors (MEGF10), revising the paradigm of SIRT1 as a context-dependent regulator of protein turnover. Existing theories attributed chronic cognitive deficits primarily to acute neuronal loss or persistent inflammation, but we show that aberrant astrocytic phagocytosis—sustained by SIRT1 downregulation and MEGF10 upregulation—represents a critical, actionable driver of long-term synaptic loss, providing a missing link between acute injury and chronic dysfunction. Despite its contributions, this study has several limitations that should be acknowledged. First, while we focused on GFAP⁺ astrocytes within the hippocampal CA1 region, emerging single-cell evidence suggests the existence of functionally heterogeneous astrocyte subpopulations across brain regions [80–82]. Whether SIRT1 exerts consistent effects in these diverse subpopulations or in other regions critically involved in TBI pathophysiology—such as the prefrontal cortex—remains an open question and warrants further investigation. ​​Second, due to ethical and practical constraints in acquiring fresh human post-TBI hippocampal samples, our human tissue analysis was limited to the cerebral cortex surrounding the lesion site. We acknowledge that although glioma tissue was used for comparative purposes, its neoplastic microenvironment is fundamentally different from that of TBI; additionally, the relatively small human sample size necessitates validation in larger cohorts. Nonetheless, this comparison strategically highlights the specificity of SIRT1 downregulation in TBI: the significantly lower SIRT1 expression in TBI compared to the hypermetabolic and dysregulated context of glioma strengthens the conclusion that SIRT1 suppression is a hallmark of TBI pathology rather than a nonspecific response to neural injury. We agree that future studies should incorporate non-neoplastic pathological controls, such as tissue resected during epilepsy surgery, to further validate the disease-context dependency of SIRT1 signaling. Third, although our data emphasize SIRT1-mediated autophagic degradation of MEGF10, we did not explore the potential involvement of post-transcriptional mechanisms—such as miRNA regulation or alternative splicing—in modulating MEGF10 expression. Subsequent studies employing RNA sequencing or RNA immunoprecipitation (RIP) assays are needed to elucidate whether SIRT1 influences these processes. Finally, while all findings were validated in a murine weight-drop TBI model, translational relevance must be further confirmed in clinical samples, such as patient-derived organoids or post-mortem tissues, and in other injury models (e.g., intracerebral hemorrhage). It is also important to note that although acute overexpression of astrocytic SIRT1 conferred beneficial effects, chronic upregulation may disrupt physiological phagocytic functions. Therefore, the safety profile and optimal treatment duration of SIRT1-targeted therapies require careful long-term evaluation. Conclusion Using cell-type-specific intervention, this study reveals that SIRT1 regulates astrocytic phagocytosis via the ATG7-autophagy-MEGF10 pathway, establishing a “glial phagocytosis-synaptic homeostasis-cognitive function” regulatory network. These findings deepen our understanding of glial-neuronal interactions and propose a new TBI treatment strategy targeting astrocytic SIRT1, offering promising translational targets for improving cognitive outcomes in neurotrauma and neurodegenerative diseases. Supplementary Information Supplementary Material 1. Supplementary Material 2. Acknowledgements We thank Weidong Zhao from China Medical University for guidance and suggestions on this article, assistance with using the TIRF microscope and imaging equipment. The graphical abstract was created with BioRender. Authors’ contributions DL, QXJ, and KC designed the research, drafted this manuscript, and provided critical revisions; QXJ, ZZ, YZ, YL, KC, JRX, and JNX performed experiments; QXJ, ZZ, DL, KC, and LZ acquired and analyzed data; DL, XYS, HLQ, and XBZ contributed to ethical application, collection, and data organization of human brain tissue samples; DL, QXJ, and KC interpreted data and critically revised the manuscript; QXJ, JS and JNX contributed to the provision of key reagents and validation of experimental models related to astrocyte isolation and culture protocols. DL, ZZ, LZ, and XBZ secured funding for the study; authors have reviewed and approved the final manuscript. Funding This work was supported by the General Program of the National Natural Science Foundation of China (Grant No. 82371406), the Young Scientists Fund of the National Natural Science Foundation of China (Grant No. 81802139), the General Program of the Natural Science Foundation of Liaoning Province (Grant No. 2024-MS-035) of DL and (Grant No. 2024-BS-067) of LZ. And the Young Scientists Fund of the Natural Science Foundation of Liaoning Province (Grant No. 2024-BS-067) of ZZ. Provincial Joint Fund General Program (Grant No. 2023-MSLH-346) of XBZ. Data availability Raw data and supporting analytical code for this study are available from corresponding authors upon justified request. Raw imaging files, qRT-PCR data, and Western blot scans are stored at China Medical University and can be provided for verification. Declarations Ethics approval and consent to participate All experimental procedures involving animals were evaluated and authorized by the IACUC at China Medical University (Approval No. CMU2023314), with strict adherence to the ARRIVE 2.0 reporting guidelines and the Chinese National Standard for Laboratory Animal Welfare (GB/T 35823 − 2018). Animals were housed in SPF facilities, and all procedures incorporated refinements to minimize pain and distress. For human tissues, ethical clearance was granted by the Medical Ethics Committee of Northern Theater General Hospital (Approval No. 2025 − 233), the designated oversight body for participant protection. The study protocol complies with the principles of the Declaration of Helsinki. This manuscript contains no identifiable patient information or clinical images. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Data Availability Statement Raw data and supporting analytical code for this study are available from corresponding authors upon justified request. Raw imaging files, qRT-PCR data, and Western blot scans are stored at China Medical University and can be provided for verification.